The major histocompatibility complex (MHC) class I molecules expressed at the cell surface are associated with a large number of different peptides so that the density of a given MHC-peptide complex is relatively low. Here we describe the properties of MHC class I molecules genetically attached to a single antigenic peptide. Cells expressing these fusion proteins are recognized by T cells specific for the particular MHC-peptide complex. Coculture of naive splenocytes with cells expressing these MHC-peptide fusion proteins and the B7.1 antigen allows the induction of primary cytotoxic T lymphocytes (CTL) in vitro. Injection of these cells into naive mice enhances the frequency of specific CTL precursors and protects against a subsequent challenge with a tumor or a virus bearing the antigenic peptide. Soluble MHC-peptide fusions were also produced in which all three components, that is, the heavy chain, B2-microglobulin and the peptide, have fused into a single-chain protein. The availability of MHC class I molecules bound to a single peptide provides valuable tools for the manipulation of CTL responses and the analysis of the selection processes in the thymus.
Summary
The major histocompatibility complex (MHC) class I molecules expressed at the cell surface are associated with a large number of different peptides so that the density of a given MHC-peptide complex is relatively low. Here we describe the properties of MHC class I molecules genetically attached to a single antigenic peptide. Cells expressing these fusion proteins are recognized by T cells specific for the particular MHC-peptide complex. Coculture of naive splenocytes with cells expressing these MHC-peptide fusion proteins and the B7.1 antigen allows the induction of primary cytotoxic T lymphocytes (CTL) in vitro. Injection of these cells into naive mice enhances the frequency of specific CTL precursors and protects against a subsequent challenge with a tumor or a virus bearing the antigenic peptide. Soluble MHC-peptide fusions were also produced in which all three components, that is, the heavy chain, B2-microglobulin and the peptide, have fused into a single-chain protein. The availability of MHC class I molecules bound to a single peptide provides valuable tools for the manipulation of CTL responses and the analysis of the selection processes in the thymus.
T
he MHC class I molecules present peptides which are mainly derived from endogenously synthesized proteins (1, 2) . These MHC-peptide complexes can be recognized by T cells bearing specific TCRs (for review see reference 3). A given cell expresses 10s-106 MHC class I molecules (4) and probably presents up to 104 different peptides or perhaps even more (5) . A specific MHC-peptide complex is therefore present in small amounts per cell. 100-200 complexes are sufficient to sensitize a target cell for lysis by an already activated CTL clone (6) . This number, however, is too low to activate CTL precursors from a naive mouse.
CTL have often proven to be both efficient and specific against viruses. Eliciting CTL against tumors has also been a major goal of immunologists. Since tumors are variants of normal cells, most peptides presented by a tumor cell are selfpeptides. Self-specific CTL are normally deleted in the thymus through a process called negative selection. The only immunogenic peptides in a tumor are actually often poorly presented, either because they are derived from poorly expressed proteins or because they bind poorly to the MHC molecules. Increasing the density of a specific MHC-peptide may help induce specific CTL, especially against a tumor, and different strategies have been taken. Mutant cell lines deficient in the translocation of endogenous peptides into the lumen of the endoplasmic reticulum (EtL) 1 can be efficiently loaded with exogenous peptides and have been used to induce specific CTL. Their use in vivo, however, is limited by allogenic or xenogenic reactivity.
MHC class I molecules are heterodimers composed of a polymorphic transmembrane heavy chain noncovalently associated with/32-microglobulin (/32m). We took advantage of their known tridimensional structure (7) (8) (9) to produce soluble K a, K b, and HLA-A2 molecules by connecting through an appropriate peptidic link the COOH terminus of the third domain of the corresponding heavy chains to the NH2 terminus of/~2m (10, 11) . These single chain MHC class I molecules are soluble in the absence of detergent (12) . The single chain K d molecule has been more extensively studied and found to bind the same repertoire of peptides as its native cell surface-expressed counterpart (13) , to be functional, and has provided useful tools to study T cell activation (14) . The tridimensional structure of several MHC class I-peptide complexes has been determined by crystallography (15) (16) (17) (18) (19) (20) . The peptide lies in a groove made of a platform of 3 sheets and two c~ helices encoded by the second and third exons of the gene encoding the heavy chain. The overall topology of these different complexes is similar, most of the interaction resulting from conserved contacts between the residues of the MHC groove and conserved structures of the peptide.
In this study, we used this information to genetically connect an antigenic peptide to the heavy chain of the mouse K d molecule. The purpose was to produce cell lines in which the density of the chosen MHC-peptide complex would be considerably increased. The expectation was that such cells would be potent immunogens capable of inducing specific CTL from naive mice. We show here that this is the case for three Ka-peptide fusions and that the corresponding transfected cells are recognized by all specific CTL tested and are highly immunogenic in vitro and in vivo. Mice vaccinated with these cells are specifically protected against a subsequent virus or tumor challenge. In addition, a soluble peptide-Ka-32m fusion was also constructed and shown to activate in vitro a specific T cell hybridoma. Thus, the extracellular part of MHC molecules can be manipulated at both ends. Such single-chain MHC-peptide complexes could be useful in vivo, especially when the native complex has a rapid dissociation rate.
Materials and Methods
Cell Lines. L (CCL1.3; American Type Culture Collection
[ATCC], Rockville, MD), LK d, and P815-Cw3 have been previously described (21) and were grown in DME supplemented with 10% FCS. CHO cells or CHO cell transfectants were grown in c~-MEM supplemented with 10% FCS or only 2% for soluble MHC production.
Plasmid Construction and Transfection. Unique XhoI and Sinai sites were introduced by site directed mutagenesis into the K d sequence at the ApaI site located at the 3' end of the leader sequence. Double strand oligonucleotides encoding the various antigenic peptides were cloned between these two sites (see Fig. 2 ). The resulting constructs were transfected into mouse L cells (ATCC CCL 1.3). Stable transfectants expressing high levels of the fusion proteins were selected by flow cytometry sorting by use of the SF1-1.1.1 mAb (ATCC HB159) in a FACStar | station (Becton Dickinson & Co., Mountain View, CA). Soluble single-chain Kd-Cw3-N10 was obtained by replacing the 5' moiety (a NotI-EcoRV fragment) of the soluble single-chain K d (10) with that from the membrane-bound Ka-Cw3-N10. The resulting construct was inserted into pFRSV (22) and transfected into CHO cells. Stable transfectants were selected and cultivated in increased concentrations of methotrexate as described (22) . Culture supernatants were tested for K d or peptide-K d secretion by immunoassay.
Immunoassay for Soluble K s. 96-well plates (CML-Microtest Luxlon, Nemours, France) were coated for 2 h with SF1-1.1.1 (antic~3) at 5/zg/ml in 100 mM carbonate buffer, pH 9.5. After washing and blocking with PBS containing 0.5% gelatin, serial dilutions of culture supernatants were added to the wells and incubated for I h. After washing with PBS, 50/A of 1/xg/ml biotinylated 20-8-4S (anti-c~l-~2) (23) Immunoprecipitation. Cells (10 6) were metabolically labeled with
[3SS]methionine (10/~Ci) for 1 h, washed, lysed, and immunoprecipitated as previously described (13) . Immunoprecipitates were analyzed by SDS-PAGE and revealed by fluorography. Peptide Elution. Cells (109) were lysed and the K a fusions immunoprecipitated as described (13) with the SF1-1.1.1 mAb. Bound peptides were extracted by boiling the immunoprecipitates in 10% acetic acid for 10 rain and purified by ultrafiltration (Centricon 10; Amicon Corp., Danvers, MA). CTL Clones and Cytolytic Assays. The CTL clones used in this study were previously described (24) (25) (26) (27) (28) , and the cytolytic assays were performed as described (26) . T Cell Hybridoma. The T cell hybridoma 9.4 (14) , product of the fusion of the Cw3/1.1 CTL clone with the 58 TCR-c~-Bhybridoma (29), has been previously described. T cell response was determined by measuring IL-2 secretion monitored by its capacity to sustain the proliferation of the IL-2-dependent cell line CTLL-2. Primary CTL Induction. Murine nucleoprotein (NP) and Cw3 primary specific CTL were generated in 5-d MLC by incubating 3 x 107 splenocytes with 5 x 105 irradiated (10,000 rad) transfected L cells. Lymphocytes were harvested on day 5 and assayed for cytolytic activity on 51Cr-labeled target cells. Cytotoxicity Assays. Cell-mediated cytolytic activities were detected in a 6oh 51Cr assay. Percent specific lysis of 104 51Cr-labeled target cells in 200/zl was determined for various lymphocyte-to- 
Results

Construction and Cell Surface Expression of H-2K d Molecules with Covalently Bound Peptides.
Oligonucleotides coding for different antigenic peptides were inserted into the K a cDNA sequence (32) between the signal sequence and the o~1 domain (Figs. 1 and 2). At the 3' junction, a spacer encoding a peptidic link made of small side chain residues was added. As listed in Table 1 , four different Kd-restricted antigenic peptides were used: A21170-185] derived from HLA-A2 (25), Cw31170-185] and the optimal 10-mer Cw31170-179], both derived from HLA-Cw3 (33) , and NP[147-155] derived from the nucleoprotein of the influenza virus (34) . The spacer between the antigenic peptide and the NH2-terminal end of the oll domain of K a was composed of two Gly residues for the 16-mers, A21170-185] and Cw31170-185]. For the Cw3 10-mer, three spacers were compared: a 10-, 20-, and a 30-residue spacer based on the Gly-Gly-Gly-Gly-Ser motif that we and others (10, 35, 36) previously used to produce single chain MHC molecules or immunoglobulins. In the construct with NP, the 10-residue spacer was used.
The constructs were transfected into mouse L cells, and stable transfectants were selected. Using flow cytometry and the SF1-1.1.1 anti-K a mAb, we determined if the different fusion proteins were expressed at the cell surface. As shown in Fig. 3 A for the Ka-A21170-185] fusion, transfected cells expressed high levels of the fusion at their surface. Similar results were found for the other fusions. The same conclusion was drawn by use of a different anti-K d mAb, 34-1-2. This suggests that the overall structure of the K d portion was not altered, as two antibodies specific for two different epitopes could recognize the fusion proteins.
Some fusion proteins have been reported to be cleaved when expressed in vivo. We wanted therefore to determine if the peptidic part of the fusion was expressed. We did this experiment for the Kd-A21170-185] fusion. Since we had no 495 Mottez et al. 
Production and Purification of Soluble K d Molecules with Covalently Bound Antigenic Peptide and fl2m.
We have previously described the construction of a single-chain K a molecule (SC-K d) with covalently attached 32m. It was produced by connecting the COOH terminus of the or3 domain of K a to the NH2 terminus of 32m (10) . This fusion was shown to specifically bind peptides (12) , select the same repertoire of peptides as the native K a molecule (13) , and specifically interact with its cognate TCR (14) . We therefore produced a soluble form of one of the peptide--K a fusion proteins, Ka-Cw3-N10. For this purpose, the COOH-terminal end of the or3 domain of Ka-Cw3-N10 was connected to the NH2-terminal end of 32m (Fig. 1 , right) through a 15-residue spacer. This construct was transfected into CHO cells with a modified DHFR used as marker. Transfected clones were selected and cultivated with increasing concentrations of methotrexate. One clone resistant to 1 mM methotrexate was selected and subcloned. The culture medium of the subclone was tested for the presence of the fusion protein by immunoassay, as described in Materials and Methods. Between 1 and 3 mg/liter was detected in a 2-to 3-d culture supernatant. The peptide--K a protein was purified from culture supernatant by immunoaffinity as previously described for SC-K a. Thus, it is possible to produce single-chain MHC-peptide complex in which all components of the nat- Fig. 3 B, all three transfectants were lysed in the absence of added peptide, while L cells expressing the native K a were not lysed. Furthermore, the level of lysis paralleled the level of cell surface expression of the fusion protein (compare Fig. 3, A and B) .
A panel of seven additional independent CTL clones was then tested with one of the transfected L cell clones (Fig.  5) . A specific lysis was observed in all cases. For most CTL clones, the percentage of lysis was >80% at an E/T ratio of 10:1. Similarly, two independent CTL clones specific for Cw3 and restricted by K a lysed L-Ka-Cw3[170-185] cells (Fig 5) . In summary, all nine CTL clones tested recognized the fusion proteins in a way similar to the K a molecule loaded with the corresponding peptide. This recognition was dose dependent.
Optimization of the Spacer Length. Four different fusions
had been constructed with the Cw3 peptide ( Fig. 1 and Materials and Methods). Three of them used the optimal Cw31170-179] and different spacers of 10, 20, and 30 residues. We wanted to compare the CTL recognition of these different fusions with that of LK a cells loaded with exogenous Cw3 peptide.
We chose transfectant clones that expressed similar levels of the different fusions as judged by flow cytometry and recognition by the SF1-1.1.1 mAb. This mAb was chosen because it recognizes an epitope in the ol3 domain (11) and was therefore expected to be less sensitive to the fused peptide or spacer. Effector/Target ratio was Kd-Cw3-N10. Recognition of Kd-Cw3-N20 was slightly better than that of Kd-Cw31170-185], while recognition of Kd-Cw3-N30 was slightly less e~cient. This suggested that the optimal spacer length was 10 residues; all subsequent experiments were performed with the Ka-Cw3-N10 fusion, hereafter referred to as Kd-Cw3.
T Cell Hybridoma Stimulation by Soluble MHC Molecules with Covalently Bound Antigenic Peptide and/82m.
We previously showed that a single-chain K d in which the heavy chain had been connected to B2m could be loaded with exogenous peptides, and that the resulting complexes could specifically interact with their cognate TCR (14) . Since L cells expressing the different peptide-K d fusions could be recognized by specific CTL, we anticipated that the soluble Ka-Cw3-B2m could specifically trigger a Ka-restricted Cw3-specific T cell hybridoma.
T cells were incubated for 24 h with purified Ka-Cw3 -~2m and SF1-1.1.1 mAb in half stoichiometric amount. Culture supernatant was tested for IL-2 content by its capacity to sustain IL-2-dependent CTLL proliferation. As shown in Table 2 , Kd-Cw3-/~2m but not SC-K a induced IL-2 secretion by the 9.4 T cell hybridoma. Antibody alone had no effect. We concluded that a heterotrimer made of the MHC heavy chain, /32m, and the antigenic peptide can therefore be mimicked by a single-chain triple fusion (all in one).
No Cw3 Peptide Can Be Eluted from Cells Expressing the Kd-Cw3 Fusion Protein. A small number of MHC-peptide
complexes presented at the cell surface is su~cient to trigger activated T cells (6). Although we could not detect cleaved fusion protein after metabolic labeling and immunoprecipiration (Fig. 4) , one could argue that CTL clones lysing the L-Kd-Cw3 cells were not recognizing the uncleaved fusion protein but rather a peptide derived from the fusion protein and presented by the cleaved fusion protein (i.e., Kd). Minute quantities of dewed fusion protein could be sufficient for CTL triggering but still undetectable biochemically.
To rule out this hypothesis, we extracted the peptides from L-Ka-Cw3 cells and showed that this peptide mixture did not contain the antigenic Cw3 peptide. One billion L-K aCw3 cells were lysed and their extract immunoprecipitated by use of the anti-K a SF1-1.1.1 antibody. After acid extraction of the immunoprecipitate, peptides were purified and 497 Mottez et al. concentrated by ultrafiltration and loaded on P815 cells. In parallel, peptides were extracted from the same number of P815 cells transfected by the HLA-Cw3 gene (hereafter referred as P815-Cw3) known to present the Cw3 peptide in the context of K a. As shown in Table 3 , peptide extracted from L-Ka-Cw3 cells did not sensitize P815 to lysis by the CAS20 CTL clone, while peptides extracted from P815-Cw3 did. This demonstrates that the antigenic peptide is not presented by LoKd-Cw3 cells and, therefore, that the CTL clone CAS20 recognizes the uncleaved fusion protein.
Coculture of Naive Splenocytes with LKd-Cw3 Cells Allows the Generation of Primary Specific CTL. Cells expressing a
high number of a unique MHC-peptide complex on their surface have been shown to activate specific CTL in vitro (37) . As L-Kd-Cw3 cells express a high level of fusion protein at their surface, and this fusion mimicks the authentic Ka-Cw3 complex, we tested the capacity of these cells to induce in vitro-specific CTL. However, when L-Kd-Cw3 cells were cocultivated with naive splenocytes from C3H-OH x C3H origin, few lytic units were recovered (Fig. 7) . We next transfected bKa-Cw3 cells with a cDNA encoding the B7.1 costimulator molecule. As shown in Fig. 7 , these cells (LKd-Cw3-B7) could now elicit primary CTL in vitro. In contrast, LK a cells expressing B7-1 and loaded with exogenous Cw3 peptide were not able to activate specific CTL in primary cultures. We next extended this observation to L cells expressing K a fused to a viral peptide (bKd-NP-B7). As found for the Kd-Cw3 fusion, L cells expressing both Kd-NP and B7.1 were able to initiate the activation of naive CTL, while LK d cells expressing B7.1 and loaded with exogenous NP peptide had no effect. These results indicate that ceils expressing different Kd-peptide fusions and the B7.1 molecule acquire the ability to specifically activate T cells in vitro; both the B7.1 molecule and the fusion protein play crucial roles in this process. Neither alone is sufficient to activate primary CTL in vitro.
In Vivo Priming of Naive Mice with Cells Expressing the K d Protein Fusion. To assess if cells expressing an MHC class
I molecule with a single covalently bound peptide were able to prime and protect mice against a subsequent tumoral challenge or an acute viral infection, we injected Ft mice (C3H-OH x C3H) intraperitoneally with L cells expressing B7.1 and the Kd-Cw3 or the Ka-NP fusions. We compared their ability to elicit specific cytolytic activity in vivo.
As shown in Fig. 8 , mice injected with L-Ka-Cw3-B7 were able to reject a lethal dose of P815-Cw3 in <13 d, while mice preimmunized with either the irradiated tumor P815-Cw3 or bKd-Cw3 rejected the tumor in 20 and 25 d, Day post challenge bound to the class I molecule through mostly conserved interactions. The NH2 terminus is deeply buried into the groove, while the COOH-terminus is more accessible. As a result, addition of a single residue at the NH2 terminus of an optimal antigenic peptide is very deleterious to the peptide-MHC interaction, while addition of few residues at the COOH terminus of the peptide is less disturbing for the interaction (39) . Moreover, relatively long peptides (up to 33 residues) have been isolated from MHC class I molecules. Pool sequencing of these peptides and comparison with the known aUelic motifs suggest that some of them may extend out of the site on their COOH-terminal end (40, 41) . Our finding that the COOH-terminal end of the peptide could be extended with a peptidic link without altering the overall structure of the Kd-peptide complex is compatible with these observations. The NH2-terminal end of the MHC class I molecule lies under the platform made of 3 sheets from the or1 and ot2 domains and is therefore unlikely to be seen by the TCR. Mage et al. (42) produced a single-chain D d molecule in which 32m has been connected to the NH2 terminus of the mature heavy chain. Our finding that peptides could be linked to the NH2 terminus of the mature K d extends this observation. Preliminary modeling of our fusion proteins suggests that the linked antigenic peptide lies in the groove of the MHC molecule, bulges out at its COOH terminus, and then passes under the 3 sheet platform. According to this model, the fusion protein would look similar to the authentic Kd-peptide complex.
In the different structures of MHC class I molecules determined by crystallography, the COOH terminus of the peptide and the NH2 terminus of the or1 domain are spaced by about 37 A . This distance could theoretically be spanned by an 11-residue connecting peptide. In agreement with this prediction, we found that the best spacer length was 10 amino acids. It should be noted, however, that other spacers (20 and 30 residues) were also efficiently recognized, suggesting that the fusion protein can accommodate different spacer lengths. This is reminiscent of what we previously found when we used the same type of spacers to connect the ectodomain of K a to 32m. As long as the spacer was/>5 amino acids long, the fusions were correctly folded (10) .
While this work was in progress, Kozono et al. (43) fused antigenic peptides to the 3 chain of soluble MHC class II-molecules. They showed that such MHC class II-peptide fusions are recognized by specific T cells. While the peptide cleft of MHC class I is more narrow at each end, our results show the feasibility of this approach for class I. Therefore, for both class I and class II, it is possible to produce molecules presenting a single peptide.
We also produced a soluble form of the Ka-Cw3 fusion by connecting the COOH-terminal end of the or3 domain of the Ka-Cw3 fusion to the NH2 terminus of 32m. This triple fusion was capable of triggering a specific T cell hybridoma. The extracellular part of MHC class I molecules can therefore be manipulated at both ends simultaneously. There is a potential advantage in using peptide-MHC fusions over peptide-MHC complexes. Peptide-MHC complexes are quite stable at 4~ or at room temperature. However, some dissociate rapidly at 37~ Their half life in injected animals is therefore expected to be short. Having the peptide covalently bound to the MHC molecules should stabilize these labile complexes and increase their biological effects.
Two lines of evidence suggest that CTL recognized the undeaved fusion protein. First, when L cells transfected with the Ka-A21170-185] fusion were radiolabeled and the fusion protein precipitated with an anti-K a antibody, a single band at the expected molecular weight was observed after electrophoresis and autoradiography. No degradation product was detected. Second, when we extracted the peptides from L-Kd-Cw3 cells, we could not detect any Cw3 peptide using a CTL clone as a readout. This is somehow surprising since the fusion protein is an endogenous protein and should be processed following the MHC class I pathway. Thus, the Cw3 peptide either is not produced by the processing machinery or is not translocated by the ~p gene products into the ER; alternatively, it is produced and degraded, presumably because it does not bind any class I molecule within the ER (44) . However, when it is attached to K a, it is protected and therefore presented at the cell surface.
Cells expressing peptide-K a fusions were found to be highly immunogenic in two experimental systems involving the P815-Cw3 tumor and the influenza virus. The immunogenicity was tested in vitro by measuring the generation of primary CTL and in vivo by testing the protection against a lethal challenge and measuring the frequency of CTL precursors. In these experiments, cells expressing the peptide-K a fusions were compared with ceils expressing K d and loaded with exogenous peptides. Exogenous peptide loading was found incapable of inducing CTL in vitro or in vivo. In vitro, but not in vivo, the B7.1 molecule was required for CTL induction. However, in vivo, a more rapid rejection of the tumor and a higher frequency of CTL precursors was found when the cells expressed both the B7.1 and fusion molecules.
Several hypotheses could account for the increased immunogenicity of cells expressing the peptide-MHC fusions over cells loaded with exogenous peptides: (a) cells expressing the peptide-MHC fusions express a higher number of specific MHC-peptide complexes per cell. As already mentioned, the number of MHC-peptide complexes per cell required is different for the recognition by an already activated CTL and for the induction of naive T cells. High numbers of peptide-MHC complexes per cell, which can be achieved by use of different strategies, including acid treatment (45) It should also be noted that transfected cells express K k and D k in addition to the peptide-K d fusion protein so that, in any case, the fused peptide is not the only one presented by the transfected cells. If TCR aggregation is important for T cell triggering, specific MHC-peptide complex density rather than number per cell may be an important parameter (47) . However, as previously noted by De Bruijn et al. {47), a relatively small increase in the density of MHC-peptide complexes is probably sufficient for the induction of a T cell response. More work is needed to discriminate between these different explanations.
In conclusion, single-chain MHC-peptide fusions can be produced for both class I and class II. These fusions may prove useful for manipulating the immune response, in particular when the antigenic peptide has a low affinity for the MHC molecule, as may often be the case for tumor-derived antigenic peptides. Thymic injection of cells expressing an MHC class I molecule bound to a single antigenic peptide or production of mice transgenic for such fusions would be invaluable for studying positive selection of T cells.
